The scientific community is undoubtedly guilty of sending erratic and confusing messages on dietary prevention of heart disease. The public has been informed that eggs are bad, then that they are good, and currently they are considered neutral. Fats were taught to be bad, but now the public is informed that some fats are good (omega-3 and omega-6 polyunsaturated fats), that animal data are neutral while trans fats are awful.
Despite repeated advice over the years by nutrition and health experts less than 0.5% of countries consume optimal fruits (300g a day) and vegetables (400 g a day) a day. More than 80% of countries consume more than the recommended red meat prescription of 100g per week.
Atrial fibrillation (AF) is the commonest arrhythmia carrying the burden of cerebral embolus (CE), systemic embolus (SE) and aggravation of heart failure (HF). The risk of emboli is increased in persona with risk factors detailed by CHADS-VASc (Congestive heart failure, Hypertension, Age more than 75 years, Diabetes, Stroke, Vascular disease, Age between 65 and 74 Years, Sex category) score of 2 or more.
Traditionally the risk of embolism with subsequent morbidity and mortality has been managed by Warfarin, a vitamin K antagonist (VKA). Warfarin has always plagued treating physicians with a narrow therapeutic index, drug interactions, and need for repeated monitoring of efficacy by the International Normalized Ratio (INR). The ROCKET AF trial reported that only 55% of patients in the warfarin arm were in the INR therapeutic range.
Repeat coronary revascularization has always been found to be increased by routine follow up coronary angiography (FUCAG) in randomized trials done in the era of balloon angioplasty and percutaneous coronary intervention (PCI) with bare metal stents. But there was never any reduction in major clinical events. Myocardial infarction was reduced with angiographic follow up (AF) than with clinical follow up (CF) in BAAS (Balloon Angioplasty and Anticoagulation Study) and TAXUS –IV trials. Previous studies included low risk patients and hence impact of FUCAG in high-risk patients was unclear.
Treatment of high blood pressure reduces mortality, heart failure and heart attacks. The American Association of Physicians recently stated in their guidelines on treatment of hypertension in people over 60 years that it was enough to bring down blood pressure below 150 mm Hg to reduce risk of death, stroke and cardiac events. If a 60 year old has had a stroke or TIA then the target should be below 140 mm Hg to prevent another stroke, similarly in a patient with diabetes, metabolic syndrome or chronic kidney disease the target should be below 140 mm Hg.
All guidelines advocate lowering of high cholesterol and low-density lipoprotein (LDL) to reduce cardiac events, stroke and mortality. Numerous randomized trials have concluded that lowering LDL levels are beneficial for clinical outcomes.
It does not necessarily mean that if both your parents or a parent died of a heart attack in their forties you too are going to suffer one. Researchers have identified about 50 genes associated with heart disease. But even if you carry all the 50 genes you can still substantially reduce your risk of a heart attack by employing simple life style measures. Healthy life style behaviour that includes not smoking, not acquiring too much weight, moderate exercise and eating healthy food is terrific strategy to improve cardiovascular health in the general population.
A recent study (NEJM 2016; 375:2349) analyzed data for participants in 3 prospective cohort trials and one cross-sectional study to test the theory that life style modification despite high-risk genes can cut down rates of a heart attack.
In the din of demonetization with its befuddling changing goal posts the dropping dead on a morning run of one of the leading gynecologists’ of Mumbai went largely unnoticed. True to form, the print and electronic media hardly raised a whisper on why a middle aged man who had numerous marathons under his belt and who regularly ran 10 kilometers every morning collapse and die whilst happily engaged in his morning run? There have been of course equally if not more serious issues to be dilated upon, ranging from lakhs of workers being waylaid and scores of people perishing while waiting their turn to draw their own money from the bank or an ATM machine. No serious commentary has emerged on the tantalizing reasons for the untimely death of a seemingly superbly fit leading gynecologist.
Physicians have for decades advised exercise as the best antidote for prevention of ill health, apart from statins, ACE inhibitors and beta-blockers. The Potsdam study unequivocally demonstrated that a healthy life consisting of moderate exercise and decent diet substantially cut down development of heart attack, stroke, diabetes and even cancer. Marathon running was considered by researchers to be the best immunization against atherosclerosis.
Dual antiplatelet therapy (DAPT) is considered standard treatment after percutaneous coronary intervention (PCI) accompanied by stent deployment. The optimal duration of DAPT after a drug eluting stent (DES) remains controversial. Six months of DAPT is the minimum duration recommended by all professional cardiology guidelines with a DES implantation.
Diabetes is associated with increased platelet and thrombin reactivity and decreased response to treatment. Diabetes is well known to trigger atherosclerosis and restenosis after PCI. It is unclear whether diabetes mandates a different protocol in DAPT duration. It has been suggested that patients with diabetes may require prolonged DAPT.
Current guidelines on treating patients with non-ST segment elevation myocardial infarction ( NSTEMI) recommend an invasive strategy because this reduces the risk of death and myocardial infarction ( MI) compared with a conservative or selectively invasive approach. The timing of the invasive strategy still remains controversial. The current European Society of Cardiology guidelines are based on old trials and a meta analysis published in 2013. The TIMACS trial including more than 3000 patients has been the largest trial on the subject to date. The study was stopped prematurely because of difficulty in enrolment and it did not meet its primary endpoint.
A meta analysis conducted in 2013 that included randomized and observational trials, comparing early invasive with delayed invasive strategies recorded nonsignificant reduction in mortality in the early invasive strategy group in the randomized trials and significant reduction in mortality in the observational data. There was however an increased rate of myocardial infarction in the early strategy group which was not significant.
The most recent meta analysis has added 3 more randomized studies to previous studies in order to better determine timing of intervention in NSTEMI. The median time between randomisation and angiography ranged from 0.5 to 14 hours in the early group, and from 18 to 86 hours in the delayed group. The researchers found in their meta analysis of 10 randomized trials that an early invasive strategy did not result in mortality benefit compared to a delayed approach. It is unlikely that a small delay in intervention would result in increased deaths in patients with NSTEMI ( J Am Coll Cardiol Intv 2016;9:2267-2276).
About 5-8% of patients undergoing percutaneous coronary intervention also suffer from atrial fibrillation (AF). Oral anticoagulation with a vitamin K antagonist is better than dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor in preventing stroke in a patient with AF. On the other hand DAPT is superior to oral anticoagulation in reducing the risk of stent thrombosis with first generation stents.
Treatment in a patient with AF who has undergone PCI must balance the risk of bleeding with that of stent thrombosis and ischemic stroke. Triple therapy consisting of DAPT and oral anticoagulation may result in bleeds with rates of 2% in the first month and 4%-12% within the first year of treatment.
The theoretical advantages of the fully bioresorbable scaffolds (BRSs) include, to begin, with the ability to dissolve after some months, restoration of vasomotion of the coronary artery, improbability of late stent thrombosis because of absence of a pro-inflammatory polymer, no hindrance during future MRI or other imaging, and avoiding jailing of a side branch.
Thiazide type diuretics are known to improve bone strength and reduce risk of fractures. Many observational studies have suggested this advantage of diuretics regarding bone strength. There is probably a positive effect on calcium balance and direct stimulation of osteoblasts. Beta-blockers may also reduce fracture risk but the jury is till out on the mechanism. Studies have shown that ACE inhibitors by blocking local angiotensin production that increases osteoclast activity increase bone strength. Some studies suggest lower fracture risk with ACE inhibitors but all do not agree. Little data is available on effect of calcium channel blockers on bone durability.
In an international prospective cohort study more than 14,000 patients undergoing non cardiac surgery were studied ( Vascular Events in Noncardiac Surgery Patients Cohort Events Evaluation-VISION). There were 4802 patients who were using an ACE inhibitor or an angiotensin II receptor blocker who were 45 years or older. The researchers studied the ramifications of withholding the ACE inhibitor / ARB a day before surgery. Compared to patients who continued with the ACE inhibitor/ ARB , the 1245 (26%) patients who stopped the drugs 24 hours before surgery had lower adverse events. The composite of death, ischemia induced injury(assessed by troponin) or strike were less (125/1245;12%) was less than in those who continued (459/3557;12.9%). There was an absolute reduction of 0.9% and relative reduction of 18% (p <0.01). Post operative hypotension was similar in both groups ( Anesthesiology; October 2016).
ACE inhibitors and ARB’s are known to produce intraoperative hypotension but thus is the first time adverse clinical effects have been recorded. It is not clear as to why the 26% patients stopped ACE inhibitor/ARB prior to non cardiac surgery. There was significantly less intraoperative hypotension in those who did stop the drugs.
About 5% of patients undergoing coronary angiography are found to have left main coronary artery (LMCA) disease. Left main disease has proved to be lethal because the left main coronary artery supplies 100% of the left ventricle (LV) myocardium in a left dominant system, and 80% of LV myocardium in a right dominant system. Surgical revascularization has been the mainstay of treatment of LMCA disease for long. The SYNTAX trial however demonstrated that patients with LMCA could be managed with paclitaxel eluting stent in patients with low and intermediate coronary artery complexity (SYNTAX score <32). The study showed similar rates of death up to 5 years with percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG). There were similar rates in major adverse cardiac events at 12 months and at 5 years (Circulation 2014;129:2388-94).
It is not uncommon to come across a patient brought into the emergency for syncope. Experienced clinicians are well aware that often despite extensive examination and investigations the cause cannot be confirmed. A recent paper has studied the prevalence of pulmonary embolism in patients admitted for syncope (NEJM 2016; 375:1524-31).
The Mayo Clinic has published a paper on the surgical approach in patients hypertrophic obstructive cardiomyopathy (HOCM) accompanied by mitral regurgitation (MR). The study has confirmed what is already well known that MR in HOCM is dependent upon systolic anterior motion (SAM) and in most patients this can be corrected by extended myectomy alone.
Hypertrophic cardiomyopathy (HCM) is characterized by asymmetrical myocardial hypertrophy plus fiber fibrosis and disarray. About one third of HCM patients have resting left ventricular outflow tract obstruction (LVOTO) with >30 mm gradient at rest. Another third have a resting gradient < 30 mm but obstruction can be triggered by exertion, increased myocardial contractility or afterload.